BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
2.830
-0.070 (-2.41%)
At close: Jul 20, 2026, 4:00 PM EDT
2.830
0.00 (0.00%)
After-hours: Jul 20, 2026, 4:10 PM EDT
BioLineRx Employees
As of December 31, 2025, BioLineRx had 24 total employees, including 20 full-time and 4 part-time employees. The number of employees decreased by 4 or -14.29% compared to the previous year.
Employees
24
Change (1Y)
-4
Growth (1Y)
-14.29%
Revenue / Employee
$58,417
Profits / Employee
-$329,292
Market Cap
12.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 24 | -4 | -14.29% | 20 | 4 |
| Dec 31, 2024 | 28 | -51 | -64.56% | 24 | 4 |
| Dec 31, 2023 | 79 | 30 | 61.22% | 79 | 0 |
| Dec 31, 2022 | 49 | 11 | 28.95% | 49 | 0 |
| Dec 31, 2021 | 38 | 0 | - | 38 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Lunai Bioworks | 29 |
| IN8bio | 18 |
| CalciMedica | 16 |
| Kiora Pharmaceuticals | 13 |
| Psyence Biomedical | 12 |
| Cocrystal Pharma | 10 |
| Intensity Therapeutics | 7 |
BLRX News
- 13 hours ago - BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 - PRNewsWire
- 12 days ago - BioLineRx (BLRX) Reveals Promising Ovarian Cancer Treatment Data - GuruFocus
- 12 days ago - BioLineRx, Hemispherian announces new preclinical data on GLIX1, PARP inhibitor - TheFly
- 12 days ago - BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model - PRNewsWire
- 7 weeks ago - BioLineRx (BLRX) Q1 2026 Earnings Transcript - The Motley Fool
- 7 weeks ago - BLRX Achieves Key Milestones in Clinical Development and Revenue Growth - GuruFocus
- 7 weeks ago - BioLineRx Earnings Call Transcript: Q1 2026 - Transcripts
- 7 weeks ago - BioLineRx Earnings release: Q1 2026 - Filings